<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04750460</url>
  </required_header>
  <id_info>
    <org_study_id>TeriCa</org_study_id>
    <nct_id>NCT04750460</nct_id>
  </id_info>
  <brief_title>Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).</brief_title>
  <acronym>TeriCa</acronym>
  <official_title>The Effect of Teriparatide on the Early Postoperative Hypocalcemia After Parathyroidectomy in Dialysis Patients: a Pilot, Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Petersburg State University, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Petersburg State University, Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot randomized controlled trial aimed to evaluate the effect of teriparatide on&#xD;
      the clinical course of hypocalcemia after parathyroidectomy for secondary hyperparathyroidism&#xD;
      in dialysis-dependent patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative hypocalcemia is a common complication after parathyroidectomy (PTx) for&#xD;
      secondary hyperparathyroidism in dialysis-dependent patients. It is known to be associated&#xD;
      with significant drop of parathyroid hormone (iPTH) level after surgery. Thus, in the present&#xD;
      study we test the hypothesis that reducing iPTH difference before/after PTx with teriparatide&#xD;
      injections immediately after surgery may alleviate clinical course of post-PTx hypocalcemia.&#xD;
&#xD;
      This is a feasible study aimed to determine the sample size for further large-scale trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total serum calcium level</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parathyroid hormone level</measure>
    <time_frame>Day 1, 2, 3, 4, 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum phosphorus level</measure>
    <time_frame>Day 1, 2, 3, 4, 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total alkaline phosphatase level</measure>
    <time_frame>Day 1, 2, 3, 4, 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total serum calcium level</measure>
    <time_frame>Day 2, 3, 4, 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ionized serum calcium level</measure>
    <time_frame>Day 1, 2, 3, 4, 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events (major cardiovascular events, fractures, arrhythmia episodes, death)</measure>
    <time_frame>up to 1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Secondary Hyperparathyroidism</condition>
  <condition>Chronic Kidney Disease-Mineral and Bone Disorder</condition>
  <condition>Dialysis</condition>
  <condition>Hypocalcemia</condition>
  <condition>Hypoparathyroidism</condition>
  <arm_group>
    <arm_group_label>Teriparatide group (10 patients)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dialysis-dependent patients underwent total parathyroidectomy with autotransplantation of parathyroid tissue, who will receive subcutaneous injections ot recombinant parathyroid hormone (Teriparatide) after surgery in addition to the standard local protocol for hypocalcemia treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group (10 patients)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Dialysis-dependent patients underwent total parathyroidectomy with autotransplantation of parathyroid tissue, receiving standard local protocol for hypocalcemia treatment (2 micrograms of alphacalcidol plus 4 grams of oral calcium daily).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>Subcutaneous injections of study drug will be assigned immediately after parathyroidectomy (20 mcg), on the 1st (20 mcg) and 2nd (10 mcg) postoperative day.</description>
    <arm_group_label>Teriparatide group (10 patients)</arm_group_label>
    <other_name>Forsteo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years;&#xD;
&#xD;
          2. Patients with end-stage renal disease (ESRD) receiving hemodialysis or peritoneal&#xD;
             dialysis treatment &gt; 3 months prior surgery;&#xD;
&#xD;
          3. Severe secondary hyperparathyroidism defined as iPTH level &gt; 800 pg/ml, followed with&#xD;
             hypercalcemia and/or hyperphosphatemia; with presence of one or more nodular or&#xD;
             diffuse parathyroid hyperplasia confirmed with CT;&#xD;
&#xD;
          4. Performed total parathyroidectomy with autotransplantation of the parathyroid tissue.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Emergency surgery;&#xD;
&#xD;
          2. Primary hyperparathyroidism as a cause of ESRD;&#xD;
&#xD;
          3. Scheduled (before surgery) blood transfusion;&#xD;
&#xD;
          4. Re-operative surgery;&#xD;
&#xD;
          5. Known allergy to the study drug.&#xD;
&#xD;
          6. Malignant neoplasms of bone tissue (primary or metastatic).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Saint-Petersburg State University Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint Petersburg State University, Russia</investigator_affiliation>
    <investigator_full_name>Novokshonov Konstantin</investigator_full_name>
    <investigator_title>MD, PHD</investigator_title>
  </responsible_party>
  <keyword>Parathyroidectomy</keyword>
  <keyword>Teriparatide</keyword>
  <keyword>Parathyroid hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Chronic Kidney Disease-Mineral and Bone Disorder</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hypocalcemia</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
    <mesh_term>Hypoparathyroidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

